$205.02 -1.61 (-0.78%)

IQVIA Holdings Inc. (IQV)

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions, and clinical research services for the healthcare and pharmaceutical industries. It combines extensive data resources with scientific expertise to help clients improve healthcare outcomes and accelerate innovation.

🚫 IQVIA Holdings Inc. does not pay dividends

Company News

Real World Evidence Solutions Research and Forecast Report 2025-2030: Growth Opportunities in Emerging Markets and Increased Focus on End-To-End Rwe Services, & Personalized and Precision Medicine
GlobeNewswire Inc. • Researchandmarkets.Com • October 1, 2025

The global real world evidence (RWE) solutions market is projected to grow from $5.42 billion in 2025 to $10.83 billion by 2030, with a 14.8% CAGR, driven by value-based care, chronic disease prevalence, and advancements in healthcare data analytics.

Healthcare's $110B AI Surge Is Picking Up Speed--and It's Just the Beginning
Benzinga • Prnewswire • July 8, 2025

The healthcare AI market is projected to surpass $110 billion by 2030, with companies developing innovative AI solutions for preventive care, diagnostics, and patient experience across various medical domains.

Jefferies shifts IQVIA stock to 'Hold', notes booking and competitive pressures - Investing.com
Investing.com • Emilio Ghigini • July 24, 2024

Jefferies downgraded IQVIA Holdings' stock to 'Hold' from 'Buy', citing slower bookings growth and increased competition in the company's data business.

Clarivate (CLVT) to Develop Unified Library Solution for Ohio - Zacks Investment Research
Zacks Investment Research • N/A • July 22, 2024

Clarivate has partnered with OhioLINK and SearchOhio to integrate their INN-Reach platforms, creating a unified library solution for Ohio. This partnership will expand Clarivate's presence in the academic market, but the company also faces near-term challenges like macroeconomic headwinds and competitive pressure.

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
The Motley Fool • [email protected] (Keith Speights) • March 17, 2024

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

Related Companies